Y-mAbs Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/7/2026

1. HUVR:IN
2. ANET
3. NKE
4. PANW
5. CL
6. SNDK
7. TAP
8. DELL
9. ROIV
10. HUBS

Go back to Y-mAbs Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments

Y-mAbs Therapeutics (YMAB) Tops Q4 EPS by 47c

March 30, 2023 4:04 PM EDT

Y-mAbs Therapeutics (NASDAQ: YMAB) reported Q4 EPS of $0.03, $0.47 better than the analyst estimate of ($0.44). Revenue for the quarter came in at $31.5 million versus the consensus estimate of $20.35 million.

Financial Guidance

Management reiterated its 2023 financial guidance including:

Anticipated DANYELZA® net product revenues of $60-$65... More